The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | ELCC 2025 highlights: AI and emerging diagnostics in lung cancer care
Deniz Koksal, MD, Hacettepe University, Ankara, Türkiye, shares key highlights from European Lung Cancer Congress 2025, where advancements in lung cancer treatment and diagnostics took center stage. The congress featured progress in targeted therapies, immunotherapies, and antibody-drug conjugates, particularly improving outcomes for patients with locally advanced disease. Prof. Koksal also discusses the growing role of emerging diagnostics, including liquid biopsy and circulating tumor DNA (ctDNA), in disease monitoring and follow-up, and the expanding integration of artificial intelligence (AI) across multiple domains. This interview took place at the ELCC 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
